AU2018323459A1 - Spirocycle compounds and methods of making and using same - Google Patents

Spirocycle compounds and methods of making and using same Download PDF

Info

Publication number
AU2018323459A1
AU2018323459A1 AU2018323459A AU2018323459A AU2018323459A1 AU 2018323459 A1 AU2018323459 A1 AU 2018323459A1 AU 2018323459 A AU2018323459 A AU 2018323459A AU 2018323459 A AU2018323459 A AU 2018323459A AU 2018323459 A1 AU2018323459 A1 AU 2018323459A1
Authority
AU
Australia
Prior art keywords
compound
solvate
tautomer
hydrate
stereoisomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018323459A
Other languages
English (en)
Inventor
Daniel J. Buzard
Cheryl A. Grice
Todd K. Jones
Michael B. SHAGHAFI
Olivia D. Weber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of AU2018323459A1 publication Critical patent/AU2018323459A1/en
Assigned to H. LUNDBECK A/S. reassignment H. LUNDBECK A/S. Request for Assignment Assignors: LUNDBECK LA JOLLA RESEARCH CENTER, INC.
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
AU2018323459A 2017-08-29 2018-08-28 Spirocycle compounds and methods of making and using same Abandoned AU2018323459A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762551721P 2017-08-29 2017-08-29
US62/551,721 2017-08-29
PCT/US2018/048372 WO2019046318A1 (en) 2017-08-29 2018-08-28 SPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF

Publications (1)

Publication Number Publication Date
AU2018323459A1 true AU2018323459A1 (en) 2020-02-20

Family

ID=65527860

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018323459A Abandoned AU2018323459A1 (en) 2017-08-29 2018-08-28 Spirocycle compounds and methods of making and using same

Country Status (27)

Country Link
US (1) US11142526B2 (https=)
EP (1) EP3675847B1 (https=)
JP (1) JP7257387B2 (https=)
KR (1) KR20200046061A (https=)
CN (1) CN111050765B (https=)
AU (1) AU2018323459A1 (https=)
BR (1) BR112020004101A2 (https=)
CA (1) CA3072923A1 (https=)
CL (1) CL2020000462A1 (https=)
CO (1) CO2020001724A2 (https=)
CR (1) CR20200089A (https=)
DO (1) DOP2020000039A (https=)
EA (1) EA202090312A1 (https=)
EC (1) ECSP20013337A (https=)
ES (1) ES2952332T3 (https=)
GE (2) GEAP202115281A (https=)
IL (1) IL272580B (https=)
JO (1) JOP20200023A1 (https=)
MA (1) MA50041A (https=)
MX (1) MX2020002251A (https=)
NI (1) NI202000014A (https=)
PE (1) PE20200664A1 (https=)
PH (1) PH12020500372A1 (https=)
SG (1) SG11202001022TA (https=)
UA (1) UA126685C2 (https=)
WO (1) WO2019046318A1 (https=)
ZA (1) ZA202001208B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20141702A1 (es) 2012-01-06 2014-11-19 Abide Therapeutics Inc Compuestos de carbamato y preparacion y uso de los mismos
US10781211B2 (en) 2016-05-12 2020-09-22 Lundbeck La Jolla Research Center, Inc. Spirocycle compounds and methods of making and using same
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
CN111032034B (zh) 2017-08-29 2023-05-02 H.隆德贝克有限公司 螺环化合物及其制造和使用方法
JP7257387B2 (ja) 2017-08-29 2023-04-13 ハー・ルンドベック・アクチエゼルスカベット スピロ環化合物並びにその作製及び使用方法
BR112021026899A2 (pt) * 2019-07-09 2022-05-10 Hoffmann La Roche Compostos heterocíclicos
WO2022043284A1 (en) * 2020-08-26 2022-03-03 F. Hoffmann-La Roche Ag Heterocyclic compounds useful as magl inhibitors
TWI904281B (zh) 2020-11-13 2025-11-11 丹麥商Ｈ 朗德貝克公司 Magl抑制劑
CA3242372A1 (en) 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (magl)
KR20250005229A (ko) 2022-05-04 2025-01-09 하. 룬드벡 아크티에셀스카브 모노아실글리세롤 리파제 억제제로서 1,1,1,3,3,3-헥사플루오로프로판-2-일 (s)-1-(피리다진-3-일카르바모일)-6 아자스피로[2.5]옥탄-6-카르복실레이트의 결정질 형태
EP4665718A1 (en) 2023-02-13 2025-12-24 Apogee Pharmaceuticals, Inc. Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2440803A1 (en) * 2001-03-07 2002-09-12 Pfizer Products Inc. Modulators of chemokine receptor activity
US20110172230A1 (en) 2006-08-23 2011-07-14 Takahiro Ishii Urea compound or salt thereof
JP2011513421A (ja) 2008-03-05 2011-04-28 ターガセプト，インコーポレイテッド サブタイプ選択的なジアザビシクロアルカンのアミド
FR2941696B1 (fr) 2009-02-05 2011-04-15 Sanofi Aventis Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
WO2010141817A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
US8575296B2 (en) 2009-09-29 2013-11-05 Polyone Corporation Polyester articles having simulated metallic or pearlescent appearance
ES2585806T3 (es) 2009-10-23 2016-10-10 Janssen Pharmaceutica N.V. Octahidropirrolo [3,4-c] pirroles disustituidos como moduladores de receptores de orexina
WO2011109277A1 (en) 2010-03-04 2011-09-09 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
FR2960875B1 (fr) * 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
EP2444084A1 (en) 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Use of PI3K inibitors for the treatment of obesity
PE20141702A1 (es) 2012-01-06 2014-11-19 Abide Therapeutics Inc Compuestos de carbamato y preparacion y uso de los mismos
KR102179599B1 (ko) 2012-09-25 2020-11-19 에프. 호프만-라 로슈 아게 이환형 유도체
JP6647592B2 (ja) 2013-07-03 2020-02-14 ルンドベック ラ ホーヤ リサーチ センター，インク． ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用
US10093630B2 (en) * 2014-05-21 2018-10-09 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
JP2018513119A (ja) * 2015-03-18 2018-05-24 アビデ セラピューティクス，インク． ピペラジンカルバメート、およびピペラジンカルバメートを製造ならびに使用する方法
TN2017000544A1 (en) 2015-07-31 2019-04-12 Pfizer 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
WO2017087858A1 (en) 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
ES2804580T3 (es) 2016-03-31 2021-02-08 Takeda Pharmaceuticals Co Compuesto heterocíclico
US10781211B2 (en) 2016-05-12 2020-09-22 Lundbeck La Jolla Research Center, Inc. Spirocycle compounds and methods of making and using same
JOP20190050A1 (ar) 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز تخترق حاجز المخ الدموي
MA46866B1 (fr) 2016-11-16 2021-11-30 H Lundbeck As Une forme cristalline d'un inhibiteur de magl
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
UA124884C2 (uk) 2016-11-16 2021-12-08 Лундбек Ла Джолла Ресеарч Центер, Інк. Фармацевтичні склади
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
CN111032034B (zh) 2017-08-29 2023-05-02 H.隆德贝克有限公司 螺环化合物及其制造和使用方法
JP7257387B2 (ja) 2017-08-29 2023-04-13 ハー・ルンドベック・アクチエゼルスカベット スピロ環化合物並びにその作製及び使用方法

Also Published As

Publication number Publication date
IL272580B (en) 2022-09-01
MX2020002251A (es) 2020-07-20
NI202000014A (es) 2020-07-28
CR20200089A (es) 2020-04-08
EP3675847A1 (en) 2020-07-08
PE20200664A1 (es) 2020-06-11
JP7257387B2 (ja) 2023-04-13
ECSP20013337A (es) 2020-04-22
ES2952332T3 (es) 2023-10-30
PH12020500372A1 (en) 2020-12-07
EP3675847B1 (en) 2023-07-12
RU2020107163A (ru) 2021-09-30
CN111050765A (zh) 2020-04-21
EA202090312A1 (ru) 2020-08-05
US11142526B2 (en) 2021-10-12
MA50041A (fr) 2020-07-08
US20200255427A1 (en) 2020-08-13
BR112020004101A2 (pt) 2020-09-24
RU2020107163A3 (https=) 2022-03-15
SG11202001022TA (en) 2020-03-30
EP3675847A4 (en) 2021-01-06
GEP20217327B (en) 2021-12-10
CN111050765B (zh) 2024-01-02
DOP2020000039A (es) 2020-08-31
UA126685C2 (uk) 2023-01-11
IL272580A (en) 2020-03-31
WO2019046318A1 (en) 2019-03-07
ZA202001208B (en) 2021-08-25
GEAP202115281A (en) 2021-08-10
CA3072923A1 (en) 2019-03-07
EP3675847C0 (en) 2023-07-12
JOP20200023A1 (ar) 2020-02-02
JP2020532545A (ja) 2020-11-12
KR20200046061A (ko) 2020-05-06
CL2020000462A1 (es) 2020-07-10
CO2020001724A2 (es) 2020-02-28

Similar Documents

Publication Publication Date Title
AU2018323459A1 (en) Spirocycle compounds and methods of making and using same
JP7323723B2 (ja) Ｎａｖ１．８阻害剤としての２－オキソイミダゾリジン－４－カルボキサミド
KR102862474B1 (ko) Parp7 억제제로서의 피리다지논
TWI789381B (zh) 雜環化合物
EP3675848B1 (en) Spirocycle compounds and methods of making and using same
AU2018271876B2 (en) Pyrazole MAGL inhibitors
AU2015323380B2 (en) Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof
EP3515897A1 (en) Piperazine carbamates and methods of making and using same
CA3105534C (en) Thiadiazole irak4 inhibitors
AU2019336671A1 (en) Muscarinic acetylcholine M1 receptor antagonists
TW202440091A (zh) Ｎａｍｐｔ調節劑
JP2019535790A (ja) Ｇｓｋ−３阻害剤
JP6193233B2 (ja) 縮環複素環化合物
RU2781639C2 (ru) Спироциклические соединения и способы их получения и применения
HK40032869B (en) Spirocycle compounds and methods of making and using same
HK40032869A (en) Spirocycle compounds and methods of making and using same
EA041386B1 (ru) Спироциклические соединения и способы их получения и применения
HK40095793A (en) Pyrazole magl inhibitors
HK40032870B (en) Spirocycle compounds and methods of making and using same
HK40032870A (en) Spirocycle compounds and methods of making and using same
HK40026545B (en) Pyrazole magl inhibitors
HK40026545A (en) Pyrazole magl inhibitors
GB2558975A (en) New compounds

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: H. LUNDBECK A/S.

Free format text: FORMER APPLICANT(S): LUNDBECK LA JOLLA RESEARCH CENTER, INC.

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted